CERE.OQ
Latest Trade
14.44USDChange
-0.70(-4.62%)Volume
71,059Today's Range
-
15.0052 Week Range
-
18.80As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 15.14 |
|---|---|
Open | 15.00 |
Volume | 71,059 |
3M AVG Volume | 8.14 |
Today's High | 15.00 |
Today's Low | 14.18 |
52 Week High | 18.80 |
52 Week Low | 9.00 |
Shares Out (MIL) | 130.86 |
Market Cap (MIL) | 1,835.67 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results And Key Business Highlights
Cerevel Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company. The Company combines understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The Company has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. The Company’s pipeline includes Tavapadon, CVL-871, CVL-865, CVL-231 and CVL-936.
Industry
Business Services
Contact Info
131 Dartmouth Street, Suite 502
BOSTON, MA
02116
United States
+1.212.2842300
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 1.94 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.